BYM338

Known as: HuCAL-based Antibody BYM338, Human Combinatorial Antibody Library-based Monoclonal Antibody BYM338 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
  • 2017
“This study illustrates that we have the potential to prevent muscle wasting and promote muscle growth in cell and animal models… (More)
Is this relevant?
2016
2016
Bimagrumab (BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size… (More)
Is this relevant?
Review
2014
Review
2014
INTRODUCTION Cachexia is a syndrome presenting with progressive unintentional weight loss and wasting and weakness of skeletal… (More)
Is this relevant?